Investigational drug · Phase 2
Tibulizumab
Also called: ZB-106
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hidradenitis Suppurativa (HS), Systemic Sclerosis (SSc), Scleroderma.
Phase 2Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "Tibulizumab"
First trial start
2025
Feb 6, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Tibulizumab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hidradenitis Suppurativa (HS)
- Systemic Sclerosis (SSc)
- Scleroderma
Approved drugs for the same conditions: Hidradenitis suppurativa · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "Tibulizumab" as an intervention, largest first.
- Tibulizumab Skin Healing and Inflammation Evaluation for Lasting DefensePivotal-lookingActive, not recruiting
Zura Bio IncIndustry
NCT06993610 · 247 participants · Start May 16, 2025 · Primary completion Sep 18, 2026
Drug: Tibulizumab Dose A; Tibulizumab Dose B · For: Hidradenitis Suppurativa (HS)
Sites: Phoenix, Arizona; Irvine, California; Los Angeles, California · 61 sites in all
- Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)Active, not recruiting
Zura Bio IncIndustry
NCT06843239 · 80 participants (planned) · Start Feb 6, 2025 · Primary completion May 2027
Drug: Tibulizumab · For: Systemic Sclerosis (SSc); Scleroderma
Sites: La Jolla, California; Los Angeles, California; Plantation, Florida · 60 sites in all
- BAFF/IL-17 Bispecific Antibody Treatment in Subjects With Primary Sjogren's SyndromePivotal-lookingWithdrawn
Matthew C. BakerAcademic, hospital or other
NCT04563195 · 0 participants · Start Feb 1, 2022 · Primary completion Dec 2023
Drug: tibulizumab (LY3090106) · For: Primary Sjogren's Syndrome
Sites: Palo Alto, California
Newest research
PubMed records naming it or its code names, newest first.
- A Comprehensive Review of Biological Agents for Lupus: Beyond Single Target.
Yang B, Zhao M, Wu H, et al. · Front Immunol 2020
- Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease.
Benschop RJ, Chow CK, Tian Y, et al. · MAbs 2019
Also in development for Hidradenitis Suppurativa (HS)
- PovorcitinibINCB054707, INCB54707Phase 312 trials
Incyte · Hidradenitis Suppurativa (HS), NonSegmental Vitiligo, Prurigo Nodularis
- BFB759Phase 32 trials
Bluefin Biomedicine, Inc. · Atopic Dermatitis (AD), Hidradenitis Suppurativa (HS)
- LT-002-158Phase 23 trials
Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. · Atopic Dermatitis (AD), Hidradenitis Suppurativa (HS)
- ORKA-002Phase 23 trials
Oruka Therapeutics, Inc. · Plaque Psoriasis, Hidradenitis Suppurativa (HS)
- CIT-013Phase 22 trials
Citryll BV · Hidradenitis Suppurativa (HS), Rheumatoid Arthritis
- CIT-013 dosePhase 22 trials
Citryll BV · Hidradenitis Suppurativa (HS), Rheumatoid Arthritis
- SL-325Phase 22 trials
Shattuck Labs, Inc. · Crohn's Disease, Hidradenitis Suppurativa (HS)
- SPY002-072SPY072Phase 22 trials
Spyre Therapeutics, Inc. · Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.